March 27, 2014
1 min read
Save

Alimera resubmits Iluvien new drug application

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Alimera Sciences has resubmitted its new drug application for Iluvien to the U.S. Food and Drug Administration, according to a press release.

The company will provide information on the FDA’s acceptance of the resubmission and a Prescription Drug User Fee Act date as it becomes available, the release said.

In the resubmission, Alimera responded to questions in the FDA’s October 2013 complete response letter and provided a safety update, which included commercial experience with Iluvien (sustained-release fluocinolone acetonide) in Europe.

click me